Glaxo Group Limited

Daniel Marcus Bradley

Roderick Alan Porter

Wai Ngor Chan

Simon Edward Ward

Kevin Thewlis

Kevin Michael Thewlis

The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof. 

Glycine transport inhibitors

Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof, are disclosed: wherein Ris Calkyl, haloCalkyl, Calkenyl, amino, monoCalkylamino or diCalkylamino; Rand R, which may be the same or different, are hydrogen, halogen, Calkyl, haloCalkyl, Calkoxy, haloCalkoxy, cyano, amino, monoCalkylamino or diCalkylamino; each R, which may be the same or different, is Calkyl, halogen, Calkyl, haloCalkyl, Calkoxy, haloCalkoxy, cyano, nitro, amino, monoCalkylamino or diCalkylamino; p is 0, 1 or 2; n is 1 or 2; Rand R, which may be the same or different, are hydrogen, halogen, Calkyl, haloCalkyl, Calkoxy, haloCalkoxy, cyano, amino, monoCalkylamino or diCalkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of Calkyl, Calkoxy, acetyl, halogen, haloCalkyl, cyano, nitro, amino, monoCalkylamino and diCalkylamino. Methods of preparation of the compounds, and uses thereof in medicine, for example treatment of schizophrenia, are also disclosed.

Growing community of inventors

Harlow, United Kingdom

Daniel Marcus Bradley